arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

AbbVie Inc.

ABBV
$288.24 ▼ -6.67 (-2.26%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
61 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Neutral
auto_awesome

Analytical Summary

AbbVie Inc. demonstrates solid fundamentals with strength in Debt to Equity. However, watch Return on Common Equity (%) which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $509.9B
Dividend Yield 0.60%
Revenue Growth 10.3% →
Op. Margin 36.0% ↘
ROIC -119.5% ↘
FCF / Share $4.13 ↗
Trailing P/E 121.1x
Price / Book —
FCF Yield 1.4%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.40B
↑ +10.3% —
Net Income Profit after all expenses
$4.22B
↑ +2167.7% —
Operating Margin Operating profit as % of sales
36.0%
↓ -4.9% 81th
FCF / Share Free cash flow per share
$4.13
↑ +134.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
76
Returns
6
Financial Health ↓
87
Cash Quality ↑
94

Dividend History

Dividend / share · sourced from SEC filings
$6.65 Latest / share
+5.7% YoY
+12.9% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 16 years · 61 quarters